Clinical
Trials
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaCondition:LymphomaMolecule:Zanubrutinib
- Study of the Safety and Pharmacokinetics of Lifirafenib (BGB-283) and PD-0325901 in Patients With Advanced or Refractory Solid TumorsCondition:Advanced solid tumorsMolecule:Lifirafenib
- A Study Tislelizumab (BGB A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal CancerCondition:Nasopharyngeal CancerMolecule:Tislelizumab
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic HCC or GC/GEJCCondition:Gastric Cancer, Hepatocellular CarcinomaMolecule:Sitravatinib + Tislelizumab
- Study of Zanubrutinib in Patients With Marginal Zone LymphomaCondition:LymphomaMolecule:Zanubrutinib
- The Study of Lifirafenib in Chinese Subjects With Local Advanced or Metastatic Malignant Solid TumorsCondition:Advanced solid tumorsMolecule:Lifirafenib
- A Study of Zanubrutinib Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaCondition:Leukemia, LymphomaMolecule:Zanubrutinib
- A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid TumorsCondition:Advanced solid tumorsMolecule:Sitravatinib + Tislelizumab
- Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid TumorsCondition:Advanced solid tumorsMolecule:BGB-425 + Tislelizumab
- Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid TumorsCondition:Advanced solid tumorsMolecule:BGB-A333 + Tislelizumab
See All Trials
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.